Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Olaf Stüve, Mariko Kita, Daniel Pelletier, Robert J. Fox, Jerome Stone, Donald E. Goodkin, Scott S. Zamvil

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

Original languageEnglish (US)
Pages (from-to)S58-S61
JournalMultiple Sclerosis
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2004

Keywords

  • Genetics
  • Immunology
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Pathology
  • Primary progressive
  • Therapies

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Mitoxantrone as a potential therapy for primary progressive multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Stüve, O., Kita, M., Pelletier, D., Fox, R. J., Stone, J., Goodkin, D. E., & Zamvil, S. S. (2004). Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Multiple Sclerosis, 10(SUPPL. 1), S58-S61. https://doi.org/10.1191/1352458504ms1032oa